Wedbush raised the firm’s price target on Oruka Therapeutics (ORKA) to $165 from $85 and keeps an Outperform rating on the shares. The firm upped the price target after Oruka announced interim results from its EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA: